Results 61 to 70 of about 24,049 (149)

Durvalumab for non-resectable stage IIIB non-small cell lung cancer—a small step or a big leap?

, 2018
Wolfram C. M. Dempke, Klaus Fenchel
openalex   +1 more source

Development of Clinical-Grade Durvalumab-680LT and Nivolumab-800CW for Multispectral Fluorescent Imaging of the PD-1/PD-L1 Axis of the Immune Checkpoint Pathway. [PDF]

Pharmaceuticals (Basel)
Huizinga HK, Hooghiemstra WTR, Linssen MD, Allersma DP, Gareb B, Dekkers BGJ, Nagengast WB, Lub-de Hooge MN.   +7 more
europepmc   +1 more source

P1.18-02 The AEGEAN Phase 3 Trial of Neoadjuvant/Adjuvant Durvalumab in Patients with Resectable Stage II/III NSCLC [PDF]

, 2019
John V. Heymach, Janis M. Taube, Tetsuya Mitsudomi, David Harpole, Mike Aperghis, L. Trani, Mark Powell, Phillip A. Dennis, Martin Reck   +8 more
openalex   +1 more source

125P Preliminary analysis on safety of the DEDALUS phase II trial: Induction chemo-durvalumab followed by reduced-dose radiotherapy and maintenance durvalumab for patients with unresectable stage III NSCLC

Andrea Riccardo Filippi, Jessica Saddi, Francesco Agustoni, D.L. Cortinovis, S. Arcangeli, Giulia Galli, Giulia Maria Stella, D. Cicognini, A. Ferrari, Catherine Klersy, P. Pedrazzoli, U. Malapelle, F. Grossi   +12 more
openalex   +1 more source

Supplementary Figure S1 from Interferon Gamma Messenger RNA Signature in Tumor Biopsies Predicts Outcomes in Patients with Non–Small Cell Lung Carcinoma or Urothelial Cancer Treated with Durvalumab

, 2023
Brandon W. Higgs, Christopher Morehouse, Katie Streicher, Philip Z. Brohawn, Fernanda Pilataxi, Ashok Gupta, Koustubh Ranade   +6 more
openalex   +1 more source

Durvalumab plus cisplatin and gemcitabine in advanced biliary tract cancer: can we do it better? [PDF]

Hepatobiliary Surg Nutr
Rimini M, Casadei-Gardini A.
europepmc   +1 more source

Efficacy of combined immunotherapy and chemotherapy in recurrent non-small cell lung cancer during durvalumab maintenance therapy: A case report. [PDF]

Oncol Lett
Maze Y, Mitsumura T, Nakahama H, Kato T, Takahashi Y, Nei Y, Hanada S, Miyamoto A, Uruga H, Fujii T, Tamaoka M.   +10 more
europepmc   +1 more source

Myocarditis induced by durvalumab in a patient with hepatocellular carcinoma: A case report. [PDF]

Saudi Pharm J
Alfehaid L, Alsuhebany N, Aldoughaim M, Bukhari R, Sait W, Alshammari K, Aziz M.   +6 more
europepmc   +1 more source

PD-L1 inhibitors combined with chemotherapy for extensive-stage small cell lung cancer: a French nationwide cohort study. [PDF]

Lancet Reg Health Eur
Jourdain H, Albin N, Monard A, Desplas D, Zureik M, Haddy N.   +5 more
europepmc   +1 more source

Exploring the impact of first-line durvalumab plus chemotherapy on advanced biliary tract cancer: a systematic review and meta-analysis. [PDF]

Oncologist
Reimann P, Schneider EM, Djanani A, Mink S, Winder T, Benda M.   +5 more
europepmc   +1 more source